Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
🔒 Full content requires a free HCP account. Register free or sign in.
NICE • MHRA • NHS England • SIGN

📖 Clinical Guideline Library

225+ evidence-based NICE, MHRA and NHS guidelines — AI-summarised and searchable, built for UK clinicians.

Filter:
NICE Oncology
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Source: NICEView full guideline on NICE ↗ See full guideline on the NICE website. ClinicaliQ Editorial Note: Sourced and indexed from NICE. Always refer…
09 Sep 2026 Read summary →
NICE
Nemolizumab for treating moderate to severe prurigo nodularis
Source: NICEView full guideline on NICE ↗ See full guideline on the NICE website. ClinicaliQ Editorial Note: Sourced and indexed from NICE. Always refer…
09 Sep 2026 Read summary →
NICE Oncology
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Test for MSI-H/dMMR before treatment: All patients with advanced or recurrent endometrial cancer should undergo microsatellite instability or mismatch repair deficiency testing prior to…
26 Aug 2026 Read summary →
NICE Respiratory / COPD / Asthma
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over (terminated evaluation)
Evaluation terminated: Brensocatib for non-CF bronchiectasis is no longer under NICE appraisal—do not initiate new treatment pathways for this indication pending alternative guidance from…
25 Aug 2026 Read summary →
NICE Gastroenterology
Ex-situ machine perfusion devices to preserve deceased donor livers for transplantation
Consider ex-situ machine perfusion as an alternative to static cold storage for deceased donor livers, particularly for higher-risk grafts (extended criteria donors, prolonged cold…
20 Aug 2026 Read summary →
NICE Oncology
Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)
This NICE evaluation was terminated, meaning lisocabtagene maraleucel is not currently recommended for routine NHS use in relapsed or refractory follicular lymphoma—do not commission…
20 Aug 2026 Read summary →
NICE
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia (terminated evaluation)
Evaluation terminated – Rilzabrutinib for immune thrombocytopenia (ITP) is no longer under NICE appraisal; refer to current NICE guidance or your local ITP treatment…
20 Aug 2026 Read summary →
NICE
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over
Donidalorsen is recommended as a preventive treatment option for recurrent hereditary angioedema (HAE) attacks in patients aged 12 years and over – consider it…
19 Aug 2026 Read summary →
NICE Oncology
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
First-line treatment option: Acalabrutinib combined with bendamustine and rituximab is recommended as a first-line treatment for untreated mantle cell lymphoma, offering an alternative to…
19 Aug 2026 Read summary →
NICE Oncology
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia
Use acalabrutinib with venetoclax ± obinutuzumab as first-line treatment for untreated CLL – this combination is recommended by NICE and offers improved outcomes compared…
19 Aug 2026 Read summary →
NICE
DMD Care UK’s guideline on orthopaedic care: NICE review
Refer boys with DMD to orthopaedic services early to prevent contractures and maintain mobility—early intervention with stretching, splinting, and positioning can delay loss of…
05 Aug 2026 Read summary →
NICE Cardiology / Cardiovascular
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated in primary…
05 Aug 2026 Read summary →
NICE Cardiology / Cardiovascular
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers, or disopyramide),…
30 Jul 2026 Read summary →
NICE Rheumatology
Osteoporosis: risk assessment
Use the FRAX tool or DXA scan results to stratify fracture risk in adults aged 50+ with risk factors (prior fracture, corticosteroid use, family…
29 Jul 2026 Read summary →
NICE Cardiology / Cardiovascular
Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)
Netarsudil evaluation by NICE was terminated, indicating it is not recommended for routine use in NHS treatment pathways for open-angle glaucoma or ocular hypertension—continue…
16 Jul 2026 Read summary →
NICE Oncology
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)
Evaluation terminated – NICE discontinued appraisal of lutetium-177 vipivotide tetraxetan; this agent is not recommended for routine NHS use and should not be prescribed…
16 Jul 2026 Read summary →
NICE
Deuruxolitinib for treating severe alopecia areata
Deuruxolitinib is recommended as a treatment option for severe alopecia areata in adults—consider initiation in patients with extensive hair loss where conventional therapies have…
15 Jul 2026 Read summary →
NICE Oncology
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer
Pembrolizumab combined with chemoradiotherapy is recommended for untreated locally advanced cervical cancer, improving survival outcomes compared to chemoradiotherapy alone—consider this combination as first-line treatment…
14 Jul 2026 Read summary →
NICE Oncology
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy
Cemiplimab is recommended as a treatment option for patients with recurrent or metastatic cervical cancer only after progression on or following platinum-based chemotherapy—ensure prior…
09 Jul 2026 Read summary →
NICE
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis
First-line topical option: Glycopyrronium bromide cream is recommended as a first-line treatment for severe primary axillary hyperhidrosis in adults, offering an effective alternative to…
09 Jul 2026 Read summary →
NICE Diabetes / Metabolic
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes
Teplizumab is recommended for people aged 8 years and over with stage 2 type 1 diabetes to delay progression to stage 3; discuss with…
09 Jul 2026 Read summary →
NICE
Perioperative care in adults
Preoperative assessment: Systematically identify and optimise modifiable risk factors (cardiovascular, respiratory, renal function, anaemia, diabetes control) before elective surgery to reduce perioperative complications and…
01 Jul 2026 Read summary →
NICE Oncology
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor
Pirtobrutinib is recommended as a treatment option for relapsed or refractory chronic lymphocytic leukaemia (CLL) specifically in patients who have progressed on a prior…
01 Jul 2026 Read summary →
NICE Neurology
Atogepant for treating migraine
Atogepant is recommended as a preventive treatment option for episodic migraine in adults; consider initiating in patients with ≥4 migraine days per month who…
30 Jun 2026 Read summary →
NICE Oncology
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
Mirvetuximab soravtansine is recommended for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients with folate receptor-alpha (FRα) positivity—confirm FRα status via…
24 Jun 2026 Read summary →
NICE
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
Daratumumab in combination with bortezomib, lenalidomide and dexamethasone is recommended as a treatment option for newly diagnosed multiple myeloma patients who are ineligible for…
24 Jun 2026 Read summary →
NICE
Seladelpar for previously treated primary biliary cholangitis
Seladelpar is recommended as an option for adults with primary biliary cholangitis (PBC) who have had an inadequate response to ursodeoxycholic acid (UDCA) and…
24 Jun 2026 Read summary →
NICE Oncology
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Serplulimab combined with carboplatin and etoposide is recommended as first-line treatment for untreated extensive-stage small-cell lung cancer (ES-SCLC) and should be considered for eligible…
18 Jun 2026 Read summary →
NICE Oncology
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)
Imlunestrant evaluation was terminated – NICE did not complete appraisal of imlunestrant for oestrogen receptor-positive HER2-negative advanced breast cancer; clinicians should refer to current…
18 Jun 2026 Read summary →
NICE Respiratory / COPD / Asthma
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
Mepolizumab is recommended for patients with uncontrolled COPD and blood eosinophils ≥100 cells/μL; check eosinophil levels before initiating treatment as this is a mandatory…
17 Jun 2026 Read summary →
NICE Oncology
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
First-line treatment option: Cemiplimab combined with platinum-based chemotherapy is recommended by NICE for patients with untreated advanced non-small-cell lung cancer (NSCLC), offering an evidence-based…
16 Jun 2026 Read summary →
NICE Oncology
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment
Tisotumab vedotin is recommended for cervical cancer patients with recurrent or metastatic disease that has progressed despite prior systemic treatment—consider this as a treatment…
11 Jun 2026 Read summary →
NICE Rare Diseases
Nusinersen and risdiplam for treating spinal muscular atrophy
Consider nusinersen or risdiplam early in SMA diagnosis – both are recommended treatment options for eligible patients and should be initiated promptly after confirmation,…
04 Jun 2026 Read summary →
NICE Oncology
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)
Nogapendekin alfa inbakicept combined with BCG is no longer recommended for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ in the UK, as NICE…
04 Jun 2026 Read summary →
NICE Oncology
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment
Consider lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma who have failed ≥2 prior systemic treatments and are ineligible for or have declined…
03 Jun 2026 Read summary →
NICE Oncology
Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma
Durvalumab combined with chemotherapy should be offered as neoadjuvant treatment followed by surgery, then adjuvant durvalumab monotherapy for eligible patients with resectable gastric or…
03 Jun 2026 Read summary →
NICE Cardiology / Cardiovascular
Sotatercept for treating pulmonary arterial hypertension
Sotatercept is recommended as a treatment option for pulmonary arterial hypertension (PAH) in patients who meet NICE criteria; verify patient eligibility and existing PAH…
03 Jun 2026 Read summary →
NICE Oncology
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer
Use amivantamab with carboplatin and pemetrexed as first-line treatment for patients with advanced NSCLC harbouring EGFR exon 20 insertion mutations, following NICE appraisal recommendations…
28 May 2026 Read summary →
NICE Rare Diseases
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over
Givinostat is recommended as an option for treating Duchenne muscular dystrophy in people aged 6 years and over – consider initiating this histone deacetylase…
28 May 2026 Read summary →
NICE
Anaphylaxis: assessment and referral after emergency treatment
Observe for biphasic reactions: Keep patients under clinical observation for at least 4-6 hours post-treatment, as up to 20% may experience a second wave…
27 May 2026 Read summary →
NICE Oncology
Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy
Osimertinib is recommended by NICE for EGFR mutation-positive unresectable locally advanced NSCLC only after prior platinum-based chemoradiotherapy has been completed, making it a sequential…
21 May 2026 Read summary →
NICE
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis
Rozanolixizumab is recommended as an option for treating antibody-positive generalised myasthenia gravis (gMG) in adults—consider as an add-on therapy for patients with inadequate response…
20 May 2026 Read summary →
NICE Respiratory / COPD / Asthma
UK Achondroplasia Network’s consensus guideline for multidisciplinary care of children and young people with achondroplasia: NICE review
Establish multidisciplinary team review at diagnosis and at key developmental stages (infancy, pre-school, school age, adolescence) to monitor for complications including spinal stenosis, foramen…
19 May 2026 Read summary →
NICE Cardiology / Cardiovascular
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving clinical workflow…
19 May 2026 Read summary →
NICE Neurology
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)
Oxybutynin is effective for neurogenic detrusor overactivity in patients aged 6+ years with spinal cord injury or spina bifida—consider as first-line antimuscarinic therapy for…
07 May 2026 Read summary →
NICE Oncology
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment
Zanidatamab is recommended by NICE as an option for HER2-positive advanced biliary tract cancer only after 1 or more prior lines of systemic treatment,…
07 May 2026 Read summary →
NICE Cardiology / Cardiovascular
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part of a…
07 May 2026 Read summary →
NICE Oncology
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer
Test for BRAF V600E mutation in patients with advanced NSCLC before considering encorafenib plus binimetinib, as this combination is only recommended for mutation-positive disease…
06 May 2026 Read summary →
NICE
Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal)
Appraisal terminated: Inebilizumab appraisal was terminated by NICE; refer to current NICE guidance and your local formulary for up-to-date treatment recommendations for IgG4-related disease…
06 May 2026 Read summary →
NICE Respiratory / COPD / Asthma
Digital technologies to support self-management of asthma: early-use assessment
Use digital asthma self-management tools (apps, web platforms, wearables) as adjuncts to standard care to help patients monitor symptoms, track triggers, and improve medication…
05 May 2026 Read summary →
NICE
Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma
Belantamab mafodotin combined with bortezomib and dexamethasone is recommended for previously treated multiple myeloma patients; consider this regimen when standard retreatment options have been…
30 Apr 2026 Read summary →
NICE
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over
Indicated for IDH-mutant gliomas post-surgery: Vorasidenib is recommended for astrocytoma or oligodendroglioma with confirmed IDH1 or IDH2 mutations in patients aged 12+ following surgical…
29 Apr 2026 Read summary →
NICE
Sodium zirconium cyclosilicate for treating hyperkalaemia
Sodium zirconium cyclosilicate is recommended as a treatment option for hyperkalaemia in adults and can be used for both acute management and chronic maintenance…
29 Apr 2026 Read summary →
NICE Oncology
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors
Ripretinib is recommended as an option for adults with advanced gastrointestinal stromal tumours who have received 3 or more prior kinase inhibitors – use…
28 Apr 2026 Read summary →
NICE Oncology
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
Pembrolizumab is recommended as neoadjuvant treatment prior to surgery for resectable locally advanced head and neck squamous cell carcinoma, followed by adjuvant pembrolizumab to…
21 Apr 2026 Read summary →
NICE Infectious Disease
Transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula
Consider transvenous embolisation in patients with spontaneous intracranial hypotension confirmed to have a cerebrospinal fluid–venous fistula, as it offers a targeted intervention when conservative…
15 Apr 2026 Read summary →
NICE Dermatology
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)
This NICE publication is marked as a terminated appraisal, so it functions as a status notice rather than an active treatment recommendation for routine…
08 Apr 2026 Read summary →
NICE Respiratory / COPD / Asthma
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals to secondary…
02 Apr 2026 Read summary →
NICE Women's Health
Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause
Fezolinetant is recommended as an option for moderate to severe vasomotor symptoms (hot flushes and night sweats) in menopausal women when hormone replacement therapy…
31 Mar 2026 Read summary →
NICE
Fertility problems: assessment and treatment
Initial assessment in primary care: Offer semen analysis to men and check ovulation status (via progesterone blood test on day 21 of cycle) in…
31 Mar 2026 Read summary →
Respiratory / COPD / Asthma
GOLD 2025 Report: Global Strategy for Prevention, Diagnosis and Management of COPD
GOLD 2025 updates COPD diagnosis criteria: spirometry FEV1/FVC
31 Mar 2026 Read summary →
Respiratory / COPD / Asthma
GINA 2024 Report: Global Strategy for Asthma Management and Prevention
GINA 2024 reinforces no SABA-only treatment for any asthma severity: all patients should receive ICS-containing controller therapy or ICS-formoterol MART as first-line to reduce…
31 Mar 2026 Read summary →
Oncology
EMA Reflection Paper on Extrapolation of Efficacy in Oncology
This EMA guideline addresses EMA Reflection Paper on Extrapolation of Efficacy in Oncology in Oncology. Use it to review current recommendation wording, eligibility criteria,…
30 Mar 2026 Read summary →
Haematology
2023 EHA Guidelines on the Management of Myeloma
This EHA guideline addresses 2023 EHA Guidelines on the Management of Myeloma in Haematology. Use it to review current recommendation wording, eligibility criteria, and…
30 Mar 2026 Read summary →
Gastroenterology
2022 ESPGHAN Guidelines on Coeliac Disease Diagnosis
This ESPGHAN guideline addresses 2022 ESPGHAN Guidelines on Coeliac Disease Diagnosis in Gastroenterology. Use it to review current recommendation wording, eligibility criteria, and implementation…
30 Mar 2026 Read summary →
Cardiology / Cardiovascular
EMA Guideline on Clinical Investigation of Medicinal Products for Heart Failure
This EMA guideline addresses EMA Guideline on Clinical Investigation of Medicinal Products for Heart Failure in Cardiology / Cardiovascular. Use it to review current…
30 Mar 2026 Read summary →
Neurology
2022 EAN/EFNS Guidelines on Dementia Diagnosis and Management
This EAN guideline addresses 2022 EAN/EFNS Guidelines on Dementia Diagnosis and Management in Neurology. Use it to review current recommendation wording, eligibility criteria, and…
30 Mar 2026 Read summary →
Nephrology
2022 ERA Guidelines on the Management of Chronic Kidney Disease
This ERA guideline addresses 2022 ERA Guidelines on the Management of Chronic Kidney Disease in Nephrology. Use it to review current recommendation wording, eligibility…
30 Mar 2026 Read summary →
ESCMID Infectious Disease
2022 ESCMID Guidelines on Candidaemia and Invasive Candidiasis
This ESCMID guideline addresses 2022 ESCMID Guidelines on Candidaemia and Invasive Candidiasis in Infectious Disease. Use it to review current recommendation wording, eligibility criteria,…
30 Mar 2026 Read summary →
Neurology
2023 EAN Guidelines on the Management of Multiple Sclerosis
This EAN guideline addresses 2023 EAN Guidelines on the Management of Multiple Sclerosis in Neurology. Use it to review current recommendation wording, eligibility criteria,…
30 Mar 2026 Read summary →
Neurology
2022 EAN Guidelines on Epilepsy Management in Adults
This EAN guideline addresses 2022 EAN Guidelines on Epilepsy Management in Adults in Neurology. Use it to review current recommendation wording, eligibility criteria, and…
30 Mar 2026 Read summary →
Rheumatology
2023 EULAR Recommendations for Systemic Lupus Erythematosus
This EULAR guideline addresses 2023 EULAR Recommendations for Systemic Lupus Erythematosus in Rheumatology. Use it to review current recommendation wording, eligibility criteria, and implementation…
30 Mar 2026 Read summary →
ESCMID Respiratory / COPD / Asthma
2021 ESCMID Guidelines for the Management of Community-acquired Pneumonia
This ESCMID guideline addresses 2021 ESCMID Guidelines for the Management of Community-acquired Pneumonia in Respiratory / COPD / Asthma. Use it to review current…
30 Mar 2026 Read summary →
ESMO Oncology
2023 ESMO Clinical Practice Guidelines: Colorectal Cancer
Covers screening recommendations for average-risk and high-risk individuals • Provides guidance on diagnostic staging and pretreatment evaluation • Addresses surgical and neoadjuvant/adjuvant treatment approaches…
30 Mar 2026 Read summary →
Rheumatology
2022 EULAR Recommendations for the Management of Rheumatoid Arthritis
This EULAR guideline addresses 2022 EULAR Recommendations for the Management of Rheumatoid Arthritis in Rheumatology. Use it to review current recommendation wording, eligibility criteria,…
30 Mar 2026 Read summary →
Rheumatology
2023 EULAR Recommendations for the Management of Gout
This EULAR guideline addresses 2023 EULAR Recommendations for the Management of Gout in Rheumatology. Use it to review current recommendation wording, eligibility criteria, and…
30 Mar 2026 Read summary →
ESMO Oncology
2023 ESMO Clinical Practice Guideline: Early Breast Cancer
Focuses on multidisciplinary management of early breast cancer including surgery, radiation, and systemic therapy • Covers genetic testing recommendations (BRCA, PD-L1, HER2) and how…
30 Mar 2026 Read summary →
ESMO Oncology
2023 ESMO Clinical Practice Guidelines: Metastatic Non-Small Cell Lung Cancer
Covers diagnostic workup and molecular profiling for metastatic non-small cell lung cancer (NSCLC) • Provides treatment algorithms based on biomarker status (EGFR, ALK, ROS1,…
30 Mar 2026 Read summary →
Gastroenterology
2023 EASL Clinical Practice Guidelines on Cirrhosis
This EASL guideline addresses 2023 EASL Clinical Practice Guidelines on Cirrhosis in Gastroenterology. Use it to review current recommendation wording, eligibility criteria, and implementation…
30 Mar 2026 Read summary →
Gastroenterology
2023 EASL-EASD-EASO Clinical Practice Guidelines for MASLD
This EASL guideline addresses 2023 EASL-EASD-EASO Clinical Practice Guidelines for MASLD in Gastroenterology. Use it to review current recommendation wording, eligibility criteria, and implementation…
30 Mar 2026 Read summary →
EASD/ESC Diabetes / Metabolic
2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease
This EASD guideline addresses 2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease in Diabetes / Metabolic. Use it to review current recommendation wording, eligibility…
30 Mar 2026 Read summary →
Gastroenterology
2022 EASL Clinical Practice Guidelines on Hepatitis C
This EASL guideline addresses 2022 EASL Clinical Practice Guidelines on Hepatitis C in Gastroenterology. Use it to review current recommendation wording, eligibility criteria, and…
30 Mar 2026 Read summary →
ESC/ERS Respiratory / COPD / Asthma
2022 ERS/ESC Guidelines on Pulmonary Hypertension
This ERS guideline addresses 2022 ERS/ESC Guidelines on Pulmonary Hypertension in Respiratory / COPD / Asthma. Use it to review current recommendation wording, eligibility…
30 Mar 2026 Read summary →
ERS Respiratory / COPD / Asthma
2023 ERS Guidelines on Sleep-disordered Breathing
This ERS guideline addresses 2023 ERS Guidelines on Sleep-disordered Breathing in Respiratory / COPD / Asthma. Use it to review current recommendation wording, eligibility…
30 Mar 2026 Read summary →
Diabetes / Metabolic
2023 ADA/EASD Consensus Report: Management of Hyperglycaemia in Type 2 Diabetes
Joint consensus update prioritising SGLT2 inhibitors and GLP-1 receptor agonists based on cardiovascular and renal comorbidities. Introduces individualised glucose targets and deprescribing guidance.
30 Mar 2026 Read summary →
ERS/ATS Respiratory / COPD / Asthma
2023 ERS/ATS Guidelines on COPD Exacerbations
Covers diagnosis and assessment of COPD exacerbations including severity grading • Provides recommendations for pharmacologic management (bronchodilators, steroids, antibiotics) • Addresses indications for non-invasive…
30 Mar 2026 Read summary →
ERS Respiratory / COPD / Asthma
2022 ERS Guidelines on Idiopathic Pulmonary Fibrosis
Covers diagnostic criteria for idiopathic pulmonary fibrosis (IPF) including HRCT patterns • Provides recommendations for antifibrotic therapy and patient selection • Addresses management of…
30 Mar 2026 Read summary →
ESC Cardiology / Cardiovascular
2022 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias
Covers risk stratification for sudden cardiac death and indications for ICD implantation • Provides management recommendations for ventricular tachycardia and ventricular fibrillation • Addresses…
30 Mar 2026 Read summary →
ESC Cardiology / Cardiovascular
2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronisation Therapy
Covers indications for cardiac pacing and cardiac resynchronization therapy (CRT) • Provides guidance on device selection, implantation techniques, and optimization • Addresses follow-up protocols,…
30 Mar 2026 Read summary →
ESC Cardiology / Cardiovascular
2024 ESC Guidelines for the Management of Atrial Fibrillation
Covers AF classification, stroke risk assessment (CHA2DS2-VASc), and bleeding risk (HAS-BLED) • Provides recommendations for rate vs rhythm control strategies • Addresses anticoagulation choices…
30 Mar 2026 Read summary →
ESC Cardiology / Cardiovascular
2023 ESC Guidelines on the Management of Endocarditis
Covers diagnostic criteria for infective endocarditis (Duke criteria) and appropriate imaging modalities • Provides antimicrobial treatment recommendations based on causative organisms and valve involvement…
30 Mar 2026 Read summary →
ESC Cardiology / Cardiovascular
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
Covers rapid diagnosis and risk stratification for acute coronary syndromes (ACS) including STEMI and NSTEMI • Provides evidence-based recommendations for reperfusion strategies (PCI vs…
30 Mar 2026 Read summary →
NICE Dermatology
Hidradenitis Suppurativa: Assessment and Management (NICE NG73)
Diagnose hidradenitis suppurativa clinically based on recurrent painful nodules, abscesses, sinus tracts, and scars localised to intertriginous areas (axillae, groin, inframammary folds), then assess…
27 Mar 2026 Read summary →
NICE Dermatology
Non-Melanoma Skin Cancer: Diagnosis and Management (NICE NG12)
Refer suspected BCC or SCC to specialist dermatology using 2-week wait pathway if diagnosis is clear; use urgent referral for lesions >4 mm depth,…
27 Mar 2026 Read summary →
NICE Dermatology
Acne Vulgaris: Management (NICE NG198)
Prescribe topical benzoyl peroxide monotherapy for mild facial acne; for mild-to-moderate acne, combine benzoyl peroxide with a topical retinoid or topical antibiotic Prescribe oral…
27 Mar 2026 Read summary →
NICE Dermatology
Atopic Eczema in Under 12s: Diagnosis and Management (NICE NG190)
Diagnose atopic eczema clinically based on itching, typical morphology and distribution, onset before age 2 years, and history of dry skin or atopic disease;…
27 Mar 2026 Read summary →
NICE Dermatology
Psoriasis: Assessment and Management (NICE NG10)
Assess psoriasis severity using BSA, PASI, or clinical judgement; classify as mild (
27 Mar 2026 Read summary →
NICE Women's Health
Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management (NICE NG126)
Offer urine pregnancy test to all women presenting with abdominal pain or vaginal bleeding; proceed to transvaginal ultrasound if positive, using this as first-line…
27 Mar 2026 Read summary →
NICE Women's Health
Urinary Incontinence and Pelvic Organ Prolapse (NICE NG123)
Offer supervised pelvic floor muscle training programmes lasting at least 6 weeks as first-line treatment for stress urinary incontinence and mixed incontinence Prescribe antimuscarinics…
27 Mar 2026 Read summary →
NICE Women's Health
Polycystic Ovary Syndrome (NICE NG88 / RCOG Guidelines)
Diagnose PCOS using Rotterdam criteria (≥2 of: irregular periods, clinical/biochemical hyperandrogenism, or polycystic ovaries on ultrasound) after excluding other diagnoses, then assess cardiovascular risk…
27 Mar 2026 Read summary →
NICE Women's Health
Fertility Problems: Assessment and Treatment (NICE CG156)
Offer initial fertility assessment after one year of regular unprotected intercourse, or after six months if the woman is aged 36 years or over.…
27 Mar 2026 Read summary →
NICE Women's Health
Endometriosis: Diagnosis and Management (NICE NG73)
Suspect endometriosis in women presenting with chronic pelvic pain, dysmenorrhoea, or deep dyspareunia; refer to gynaecology if symptoms persist after adequate trial of NSAIDs…
27 Mar 2026 Read summary →
NICE Women's Health
Menopause: Diagnosis and Management (NICE NG23)
Diagnose menopause clinically in women aged ≥45 years presenting with vasomotor or genitourinary symptoms without routine FSH testing; reserve FSH testing only for those…
27 Mar 2026 Read summary →
NICE Men's Health
Testicular Cancer: Diagnosis and Management (NICE NG303)
Refer men with testicular lump or swelling urgently to urology within 2 weeks without delaying for primary care ultrasound; perform scrotal ultrasound as first-line…
27 Mar 2026 Read summary →
NICE Men's Health
Erectile Dysfunction: Assessment and Management (NICE CG1097)
Take a sexual history exploring onset, severity, partner concerns and quality of life impact; simultaneously assess cardiovascular risk and screen for diabetes, hypertension, hyperlipidaemia,…
27 Mar 2026 Read summary →
NICE Men's Health
Testosterone Deficiency in Men: Investigation and Management (BSSM Guidelines)
Measure serum testosterone between 08:00–11:00 on two separate occasions (repeat if initial result 9–12 nmol/L); confirm deficiency only when total testosterone
27 Mar 2026 Read summary →
NICE Men's Health
Lower Urinary Tract Symptoms in Men: Assessment and Management (NICE CG97)
Obtain focused history and perform urinalysis (dipstick) to exclude urinary tract infection before further investigation in all men presenting with lower urinary tract symptoms.…
27 Mar 2026 Read summary →
NICE Men's Health
Prostate Cancer: Diagnosis and Management (NICE NG131)
Offer PSA testing with risk calculators (such as ERSPC) to men aged 50–69 years on request, and to men aged 40–49 years with African…
27 Mar 2026 Read summary →
NICE Infectious Disease
HIV Testing: Increasing Uptake Among People Who May Have Undiagnosed HIV (NICE PH33)
Offer opt-out HIV testing in emergency departments, sexual health clinics, and antenatal services to maximise identification of undiagnosed HIV cases without requiring explicit patient…
27 Mar 2026 Read summary →
NICE Infectious Disease
COVID-19: Managing the Long-Term Effects (NICE NG188)
Diagnose long COVID when symptoms persist for more than 4 weeks after acute COVID-19 infection and alternative diagnoses have been excluded; undertake baseline assessment…
27 Mar 2026 Read summary →
NICE Infectious Disease
Tuberculosis (NICE NG33)
Offer TB testing to all contacts of patients with active pulmonary or laryngeal TB within two weeks of case notification using IGRA (preferred) or…
27 Mar 2026 Read summary →
NICE Infectious Disease
Cellulitis and Erysipelas: Antimicrobial Prescribing (NICE NG141)
For non-severe cellulitis in adults, prescribe oral flucloxacillin 500 mg four times daily; use cephalexin 500 mg four times daily if penicillin-allergic • For…
27 Mar 2026 Read summary →
NICE Infectious Disease
Pneumonia in Adults: Diagnosis and Management (NICE CG191)
Use CRB65 score in primary care to stratify CAP severity (1 point each for confusion, respiratory rate ≥30, systolic BP
27 Mar 2026 Read summary →
NICE Infectious Disease
Urinary Tract Infections in Adults (NICE NG112)
Do not treat asymptomatic bacteriuria in non-pregnant women or men with antibiotics • For uncomplicated cystitis in women, prescribe nitrofurantoin 100 mg twice daily…
27 Mar 2026 Read summary →
NICE Infectious Disease
Sepsis: Recognition, Diagnosis and Early Management (NICE NG51)
Use qSOFA tool (altered mental state, systolic BP ≤100 mmHg, respiratory rate ≥22) or NEWS2 score to identify suspected sepsis in adults and escalate…
27 Mar 2026 Read summary →
NICE Gastroenterology
Pancreatitis (NICE NG104)
Confirm acute pancreatitis diagnosis using serum lipase (or amylase if unavailable) with characteristic clinical features; perform baseline assessment including FBC, U&Es, LFTs, glucose, calcium,…
27 Mar 2026 Read summary →
NICE Gastroenterology
Acute Upper Gastrointestinal Bleeding in Over 16s (NICE CG141)
Use Glasgow-Blatchford score at initial assessment to stratify risk and determine whether patients can be managed as outpatients or require admission Insert two large-bore…
27 Mar 2026 Read summary →
NICE Gastroenterology
Cirrhosis in Over 16s: Assessment and Management (NICE NG50)
Perform upper endoscopy to screen all cirrhosis patients for oesophageal varices; if present, offer variceal band ligation and initiate non-selective beta-blockers (propranolol or carvedilol)…
27 Mar 2026 Read summary →
NICE Gastroenterology
Hepatitis B (Chronic): Diagnosis and Management (NICE NG133)
Assess all newly diagnosed chronic hepatitis B patients with HBsAg, anti-HBc, HBeAg, anti-HBe, quantitative HBV DNA, ALT, and liver function tests before treatment decisions…
27 Mar 2026 Read summary →
NICE Gastroenterology
Coeliac Disease: Recognition, Assessment and Management (NICE NG20)
Test for coeliac disease using tissue transglutaminase (tTG) IgA antibodies as first-line serology, with concurrent total IgA measurement; if IgA deficient, use IgG-based tests…
27 Mar 2026 Read summary →
NICE Gastroenterology
Irritable Bowel Syndrome in Adults: Diagnosis and Management (NICE CG61)
Offer structured dietary and lifestyle advice as first-line treatment, including consideration of a low FODMAP diet if standard measures are insufficient, before prescribing antispasmodics,…
27 Mar 2026 Read summary →
NICE Rheumatology
Osteoarthritis: Care and Management (NICE CG177)
Offer all patients with osteoarthritis structured information about self-management, weight management, and both land-based and aquatic exercise programmes as first-line treatment before considering pharmacological…
27 Mar 2026 Read summary →
NICE Rheumatology
Systemic Lupus Erythematosus (BSR Guidelines)
Diagnose SLE using combination of clinical features plus positive ANA with anti-dsDNA or anti-Smith antibodies, and refer to rheumatology if SLE suspected Screen all…
27 Mar 2026 Read summary →
NICE Rheumatology
Axial Spondyloarthritis: Diagnosis and Management (NICE NG65)
Refer adults to rheumatology if they present with chronic back pain (≥3 months) plus any of: inflammatory back pain features, elevated inflammatory markers, HLA-B27…
27 Mar 2026 Read summary →
NICE Rheumatology
Psoriatic Arthritis: Assessment and Management (NICE NG65)
Refer to rheumatology for diagnostic assessment if psoriatic arthritis is suspected in patients with psoriasis and joint symptoms, regardless of psoriasis severity Start NSAIDs…
27 Mar 2026 Read summary →
NICE Rheumatology
Gout: Diagnosis and Management (NICE NG219)
Diagnose acute gout clinically (sudden joint pain, erythema, swelling) and confirm with serum urate level plus polarising microscopy of synovial fluid showing needle-shaped monosodium…
27 Mar 2026 Read summary →
NICE Rheumatology
Osteoporosis: Assessing the Risk of Fragility Fracture (NICE CG146)
Use DEXA scan to measure BMD in women aged ≥65 years, men aged ≥70 years, and younger adults with osteoporosis risk factors • Use…
27 Mar 2026 Read summary →
NICE Mental Health / Psychiatry
Obsessive-Compulsive Disorder and Body Dysmorphic Disorder (NICE CG31)
Diagnose OCD and BDD through systematic assessment of intrusive thoughts, images or impulses combined with repetitive behaviours or mental acts that cause significant distress…
27 Mar 2026 Read summary →
NICE Mental Health / Psychiatry
Self-Harm: Assessment, Management and Preventing Recurrence (NICE NG225)
Conduct comprehensive psychosocial assessment within 48 hours of all self-harm presentations (including low-lethality harm) to inform risk stratification and care planning, followed by follow-up…
27 Mar 2026 Read summary →
NICE Mental Health / Psychiatry
Eating Disorders: Recognition and Treatment (NICE NG69)
Use SCOFF questionnaire or validated screening tool in primary care to assess for weight loss, food restriction, compensatory behaviours and body image concerns when…
27 Mar 2026 Read summary →
NICE Mental Health / Psychiatry
Post-Traumatic Stress Disorder (NICE NG116)
Offer trauma-focused cognitive behavioural therapy (TF-CBT) or eye movement desensitisation and reprocessing (EMDR) as first-line psychological treatment, delivered by trained practitioners for 8–12 sessions…
27 Mar 2026 Read summary →
NICE Mental Health / Psychiatry
ADHD: Diagnosis and Management (NICE NG87)
Refer suspected ADHD cases (presenting with inattention, hyperactivity, impulsivity, or functional impairment) to specialist services (paediatrician, psychiatrist, or specialist ADHD nurse) for diagnosis using…
27 Mar 2026 Read summary →
NICE Mental Health / Psychiatry
Bipolar Disorder: Assessment and Management (NICE NG185)
Refer urgently to specialist psychiatry if bipolar disorder is suspected; diagnosis must be made by specialists using ICD-10 or DSM-5 criteria For acute mania…
27 Mar 2026 Read summary →
NICE Mental Health / Psychiatry
Schizophrenia: Psychosis and Schizophrenia in Adults (NICE NG224)
Offer oral antipsychotics as first-line treatment for first-episode psychosis at the lowest effective dose, with long-acting injectables reserved for patients with adherence concerns or…
27 Mar 2026 Read summary →
NICE Neurology
Transient Loss of Consciousness (NICE CG109)
Obtain detailed witness account documenting prodrome, colour during episode, duration of unconsciousness, injury pattern, and postictal confusion to distinguish between syncope and seizure Perform…
27 Mar 2026 Read summary →
NICE Neurology
Motor Neurone Disease: Assessment and Management (NICE NG42)
Refer suspected MND urgently to a specialist neurology centre for diagnosis confirmation by an MND-experienced neurologist using clinical examination, EMG/NCS, imaging, and genetic testing…
27 Mar 2026 Read summary →
NICE Neurology
Stroke Rehabilitation in Adults (NICE NG236)
Initiate mobilisation within 24 hours of stroke admission and perform swallowing assessment before allowing oral intake to prevent aspiration complications Deliver structured, task-specific, repetitive…
27 Mar 2026 Read summary →
NICE Neurology
Headaches in Over 12s: Diagnosis and Management (NICE CG150)
Take a focused history documenting headache onset, frequency, duration, severity, associated symptoms, and functional impact to distinguish primary headaches from secondary causes requiring investigation…
27 Mar 2026 Read summary →
NICE Neurology
Multiple Sclerosis in Adults: Management (NICE NG220)
Initiate disease-modifying therapy (DMT) in all adults with relapsing-remitting MS immediately upon diagnosis using first-line agents (interferon beta, glatiramer acetate, or teriflunomide), escalating to…
27 Mar 2026 Read summary →
NICE Neurology
Parkinson’s Disease in Adults (NICE NG71)
Start levodopa at low dose with titration based on response in patients with early motor symptoms, or use dopamine agonists (ropinirole/pramipexole) as first-line in…
27 Mar 2026 Read summary →
NICE Oncology
Head and Neck Cancers: Diagnosis and Management (NICE NG36)
Refer urgently (two-week wait) any adult with unexplained persistent hoarseness, dysphagia, otalgia, oral ulceration lasting more than 3 weeks, or suspicious neck lump for…
27 Mar 2026 Read summary →
NICE Oncology
Cervical Cancer: Diagnosis and Management (NICE NG167)
Perform colposcopy with ≥4 biopsies from different quadrants for all abnormal cervical cytology results to establish histological diagnosis Stage all suspected invasive cervical cancer…
27 Mar 2026 Read summary →
NICE Oncology
Non-Hodgkin’s Lymphoma: Diagnosis and Management (NICE NG52)
Refer urgently via suspected cancer pathway any patient with persistent lymphadenopathy (lymph nodes >1 cm short axis) or splenomegaly without clear infective cause lasting…
27 Mar 2026 Read summary →
NICE Oncology
Multiple Myeloma: Diagnosis and Management (NICE NG35)
Proteasome inhibitors (bortezomib, carfilzomib) combined with immunomodulatory drugs (lenalidomide) and dexamethasone have become standard first-line therapy for transplant-eligible myeloma patients. Daratumumab (anti-CD38 monoclonal antibody)…
27 Mar 2026 Read summary →
NICE Oncology
Bladder Cancer: Diagnosis and Management (NICE NG2)
Blue light cystoscopy with hexaminolevinate improves detection of recurrent bladder tumours compared to white light cystoscopy alone, particularly for carcinoma in situ. Intravesical BCG…
27 Mar 2026 Read summary →
NICE Oncology
Oesophago-Gastric Cancer: Assessment and Management (NICE NG83)
Multimodal treatment with neoadjuvant chemotherapy followed by surgical resection improves survival for locally advanced oesophago-gastric junction and gastric adenocarcinomas. HER2 testing is mandatory for…
27 Mar 2026 Read summary →
NICE Oncology
Pancreatic Cancer in Adults: Diagnosis and Management (NICE NG85)
CT scan with pancreatic protocol (arterial and portal venous phase) is required for all suspected pancreatic cancer, with CA19-9 as supplementary tumour marker rather…
27 Mar 2026 Read summary →
NICE Oncology
Melanoma: Assessment and Management (NICE NG14)
Excise primary melanomas with 2 cm margins if Breslow thickness ≤2 mm, or 1–2 cm margins if >2 mm, tailored to tumour characteristics and…
27 Mar 2026 Read summary →
NICE Oncology
Ovarian Cancer: Recognition and Initial Management (NICE NG241)
Perform CA125 blood test and pelvic ultrasound (including ovarian assessment) as first-line investigations in primary care when ovarian cancer is suspected based on persistent…
27 Mar 2026 Read summary →
NICE Oncology
Prostate Cancer: Diagnosis and Management (NICE NG131)
Offer PSA testing to men aged 50–69 years after informed discussion of benefits and harms; consider testing men aged 40–49 with family history or…
27 Mar 2026 Read summary →
NICE Oncology
Colorectal Cancer: Diagnosis and Management (NICE NG151)
Refer adults with rectal bleeding plus abdominal pain, change in bowel habit, weight loss, iron-deficiency anaemia, or age >60 with unexplained symptoms for urgent…
27 Mar 2026 Read summary →
NICE Diabetes / Metabolic
Tirzepatide for Managing Overweight and Obesity (NICE TA1026)
Prescribe tirzepatide to adults with BMI ≥35 kg/m² or BMI 30–34.9 kg/m² with weight-related comorbidities, initiating treatment in specialist weight management services or trained…
27 Mar 2026 Read summary →
NICE Diabetes / Metabolic
Semaglutide for Managing Overweight and Obesity (NICE TA875)
Initiate semaglutide only in specialist obesity services or via shared care with clear primary-secondary care protocols for adults with BMI ≥30 kg/m² or BMI…
27 Mar 2026 Read summary →
NICE Diabetes / Metabolic
Gestational Diabetes: Diagnosis and Treatment (NICE NG3)
Perform a 2-hour 75 g OGTT between 24–28 weeks in women with GDM risk factors; diagnose GDM if fasting glucose ≥5.6 mmol/L or 2-hour…
27 Mar 2026 Read summary →
NICE
Diabetic Foot Problems: Prevention and Management (NICE NG19)
Perform annual foot risk assessment using structured approach in all people with diabetes; stratify those with sensory neuropathy, reduced ankle mobility, or previous ulceration…
27 Mar 2026 Read summary →
NICE Diabetes / Metabolic
Non-Alcoholic Fatty Liver Disease: Assessment and Management (NICE NG49)
Use FIB-4 or NAFLD Fibrosis Score in primary care to stratify fibrosis risk in adults with metabolic risk factors (type 2 diabetes, obesity, metabolic…
27 Mar 2026 Read summary →
NICE Diabetes / Metabolic
Obesity: Identification, Assessment and Management (NICE CG189)
Use BMI thresholds to identify obesity (≥30 kg/m² in adults; ≥27.5 kg/m² in Asian populations) and offer structured first-line weight loss interventions combining 600…
27 Mar 2026 Read summary →
NICE Respiratory / COPD / Asthma
Dupilumab for Treating Moderate-to-Severe Atopic Dermatitis (NICE TA534)
Initiate dupilumab in adults and adolescents aged 12+ with moderate-to-severe atopic dermatitis only when topical corticosteroids have failed or are inadvisable, using induction dose…
27 Mar 2026 Read summary →
NICE Respiratory / COPD / Asthma
Mepolizumab for Treating Severe Refractory Eosinophilic Asthma (NICE TA431)
Initiate mepolizumab 100 mg subcutaneously once monthly only in adults with severe eosinophilic asthma inadequately controlled on high-dose inhaled corticosteroids plus long-acting beta-2 agonists,…
27 Mar 2026 Read summary →
NICE Respiratory / COPD / Asthma
Bronchiectasis (non-CF): Diagnosis and Management (NICE NG117)
Suspect bronchiectasis in patients presenting with chronic productive cough or recurrent respiratory infections and refer for High-Resolution CT chest imaging; investigate all newly diagnosed…
27 Mar 2026 Read summary →
NICE Respiratory / COPD / Asthma
Obstructive Sleep Apnoea/Hypopnoea Syndrome (NICE NG202)
Use STOP-BANG questionnaire in primary care to screen for OSAHS and refer to sleep services if clinical suspicion is high based on excessive daytime…
27 Mar 2026 Read summary →
NICE Respiratory / COPD / Asthma
Idiopathic Pulmonary Fibrosis: Diagnosis and Management (NICE NG163)
Suspect IPF in adults aged >50 presenting with unexplained progressive dyspnoea, cough, or fatigue with significant smoking history or occupational exposure, and refer urgently…
27 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Empagliflozin for Treating Chronic Heart Failure with Reduced Ejection Fraction (NICE TA773)
Initiate empagliflozin 10 mg once daily as add-on therapy to standard HFrEF treatment (ACE inhibitors, beta-blockers, and aldosterone antagonists) in adults with reduced ejection…
27 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Aortic Valve Disease: TAVI and Surgical Replacement (NICE TA631)
Offer TAVI as first-line intervention for symptomatic aortic stenosis in patients at high or prohibitive surgical risk, or with severe comorbidities precluding surgery, following…
27 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Stroke and TIA: Diagnosis and Initial Management (NICE NG128)
Use FAST recognition (Face, Arms, Speech, Time) in primary care to identify suspected stroke and arrange immediate hospital admission as a medical emergency Assess…
27 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Peripheral Arterial Disease: Diagnosis and Management (NICE CG147)
Use ABPI measurement as first-line investigation in primary care; refer to secondary care if ABPI ≤0.9 • Prescribe aspirin 75 mg daily for all…
27 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Cardiovascular Disease: Risk Assessment and Reduction (NICE NG238)
Perform CVD risk assessment using Framingham equation or QRISK3 in all adults aged 40–74 years; initiate atorvastatin 20 mg daily if 10-year risk ≥10%…
27 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Venous Thromboembolic Diseases (NICE NG158)
Use two-level Wells score or revised Geneva score combined with D-dimer testing in low-risk suspected PE; proceed directly to CT pulmonary angiography in high-risk…
27 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Stable Angina: Management (NICE CG126)
Initiate all stable angina patients on beta-blocker or rate-limiting calcium channel blocker (diltiazem/verapamil) plus aspirin and high-intensity statin; add ACE inhibitor if left ventricular…
27 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Heart Failure: Diagnosis and Management (NICE NG106)
Use NT-BNP or BNP testing in primary care to rule out heart failure; refer urgently to secondary care if elevated with compatible symptoms, and…
27 Mar 2026 Read summary →
NICE Respiratory / COPD / Asthma
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
Dupilumab is recommended for maintenance treatment of uncontrolled COPD only in patients with blood eosinophil count ≥400 cells/μL, as this biomarker predicts treatment response…
26 Mar 2026 Read summary →
NICE Mental Health / Psychiatry
Depression in Adults: Treatment and Management (NICE NG222)
Abandon severity-based classification and instead assess each patient's individual need, preference, and symptom severity to personalise treatment selection • Offer explicit choice between psychological…
25 Mar 2026 Read summary →
NICE Mental Health / Psychiatry
Generalised Anxiety Disorder and Panic Disorder in Adults (NICE CG113)
Initiate treatment with education and self-help resources (bibliotherapy); escalate to individual CBT or applied relaxation only if insufficient response • Prescribe sertraline as first-line…
25 Mar 2026 Read summary →
NICE Neurology
Dementia: Assessment, Management and Support (NICE NG97)
Use cognitive testing (MMSE or MoCA) combined with appropriate imaging to confirm dementia diagnosis • Prescribe acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) for mild-moderate…
25 Mar 2026 Read summary →
NICE Neurology
Epilepsies: Diagnosis and Management (NICE NG217, 2022 update)
Refer patients with suspected first seizure to an epilepsy specialist within 2 weeks of presentation For focal onset seizures, initiate lamotrigine or levetiracetam as…
25 Mar 2026 Read summary →
NICE Oncology
Early Breast Cancer: Diagnosis and Management (NICE NG101)
Perform triple assessment (clinical examination, imaging, and biopsy) for all suspicious breast lesions to confirm diagnosis before treatment planning Offer breast-conserving surgery with axillary…
25 Mar 2026 Read summary →
NICE Oncology
Lung Cancer: Diagnosis and Management (NICE NG122)
Arrange urgent chest CT within 2 weeks for patients with suspected lung cancer via 2-week wait referral pathway Perform EGFR mutation testing for all…
25 Mar 2026 Read summary →
NICE Rheumatology
Rheumatoid Arthritis in Adults: Management (NICE NG100)
Start methotrexate within 3 months of persistent synovitis diagnosis, combined with short-term bridging corticosteroids • Adopt treat-to-target strategy aiming for remission or low disease…
25 Mar 2026 Read summary →
NICE Gastroenterology
Ulcerative Colitis: Management (NICE NG130)
Treat mild-moderate ulcerative colitis with oral mesalazine and rectal 5-ASA as first-line therapy, and use prednisolone for induction of remission in moderate-severe disease Maintain…
25 Mar 2026 Read summary →
NICE Gastroenterology
Crohn’s Disease: Management (NICE NG129)
Use prednisolone or budesonide as first-line induction therapy for active Crohn's disease, or consider exclusive enteral nutrition as an alternative induction strategy • Prescribe…
25 Mar 2026 Read summary →
NICE Infectious Disease
Antimicrobial Stewardship: Systems and Processes for Effective Antimicrobial Medicine Use (NICE NG15)
Document the clinical indication, dose, route, and planned review/stop date on every antibiotic prescription at the point of initiation Review all intravenous antibiotic therapy…
25 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Hypertension in Adults: Diagnosis and Management (NICE NG136)
Diagnose hypertension using clinic BP ≥140/90 mmHg confirmed with ambulatory or home blood pressure monitoring, then initiate treatment if stage 1 hypertension with age…
25 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Acute Coronary Syndromes (NICE NG185)
Initiate dual antiplatelet therapy with aspirin plus ticagrelor or prasugrel for all NSTEMI patients unless contraindicated, continuing for 12 months post-ACS unless bleeding risk…
25 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Atrial Fibrillation: Diagnosis and Management (NICE NG196)
Use CHA2DS2-VASc score to stratify stroke risk and offer anticoagulation to men scoring ≥2 and women scoring ≥3 (consider treatment at scores of ≥1…
25 Mar 2026 Read summary →
NICE Diabetes / Metabolic
Type 2 Diabetes in Adults: Management (NICE NG28, 2024 Update)
Initiate metformin as first-line therapy in type 2 diabetes unless eGFR
25 Mar 2026 Read summary →
NICE Diabetes / Metabolic
Type 1 Diabetes in Adults: Diagnosis and Management (NICE NG17)
Offer multiple daily injection (MDI) basal-bolus insulin regimen as first-line treatment for all adults with type 1 diabetes, with continuous subcutaneous insulin infusion (CSII)…
25 Mar 2026 Read summary →
NICE Respiratory / COPD / Asthma
Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management (NICE NG115)
Confirm COPD diagnosis with spirometry showing post-bronchodilator FEV1/FVC ratio
25 Mar 2026 Read summary →
NICE Respiratory / COPD / Asthma
Asthma: Diagnosis, Monitoring and Chronic Asthma Management (NICE NG80/BTS)
Diagnose asthma only with objective evidence of reversible airflow obstruction or bronchial hyperresponsiveness, not on clinical symptoms alone Initiate Step 2 treatment by adding…
25 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
Insert a catheter-based left ventricular microaxial flow pump in patients with acute cardiogenic shock refractory to medical therapy and inotropic support, as a bridge…
25 Mar 2026 Read summary →
NICE Cardiology / Cardiovascular
Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
Percutaneous insertion of catheter-based left ventricular microaxial flow pumps may be considered for patients with acute cardiogenic shock refractory to medical therapy and intra-aortic…
25 Mar 2026 Read summary →
NICE Oncology
Kidney cancer: diagnosis and management
I appreciate your request, but I need to let you know that you've provided only the header/metadata of a NICE guideline, not the actual…
19 Mar 2026 Read summary →
NICE Oncology
Kidney cancer
I appreciate your request, but I need to point out that you've provided only the title and metadata for a NICE guideline on kidney…
19 Mar 2026 Read summary →
NICE
Artificial intelligence (AI) technologies to help detect or characterise colorectal polyps
Use AI-assisted polyp detection systems during colonoscopy to improve adenoma detection rates, particularly in colonoscopists with baseline detection rates below 25% • Implement real-time…
19 Mar 2026 Read summary →
NICE
Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation
Offer off-pump minimal access mitral valve repair with artificial chordae insertion to patients with mitral regurgitation who are suitable candidates and meet criteria for…
18 Mar 2026 Read summary →
NICE Mental Health / Psychiatry
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over
Offer ruxolitinib cream as a treatment option for non-segmental vitiligo in patients aged 12 years and over who have involvement of
17 Mar 2026 Read summary →
NICE Oncology
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)
I appreciate your request, but I need to be transparent: the content provided only includes the title, metadata, and editorial notes - it doesn't…
17 Mar 2026 Read summary →
NICE
12 SQ-Bet SLIT for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen in people 5 years and over
SQ-Bet SLIT is recommended for moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen in patients aged ≥5 years, offering a non-pharmacological…
06 Aug 2025 Read summary →
NICE Oncology
Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment
Use AI technologies as an adjunct to clinical assessment when triaging skin lesions in the urgent suspected cancer pathway, but do not use as…
01 May 2025 Read summary →
NICE Respiratory / COPD / Asthma
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites
Consider 12 SQ-HDM SLIT as a treatment option for patients with allergic rhinitis and/or allergic asthma caused by house dust mite sensitisation who have…
05 Mar 2025 Read summary →
NICE
Digital technologies for managing non-specific low back pain: early value assessment
Consider digital technologies (apps, wearables, online programmes) as adjuncts to standard care for non-specific low back pain, particularly for patient engagement and self-management adherence…
05 Mar 2024 Read summary →
NICE
Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment
Virtual reality exposure therapy (VRET) can be considered as an alternative to traditional in-vivo exposure for agoraphobia when patients refuse or are unable to…
15 Nov 2023 Read summary →
NICE
Intrapartum care
Continuous fetal monitoring is recommended for women at high risk of intrapartum complications – use cardiotocography (CTG) for those with pre-existing maternal conditions, previous…
29 Sep 2023 Read summary →
NICE
KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment
Use KardiaMobile 6L as a practical tool to monitor QT interval prolongation in adults on antipsychotic medications, enabling earlier detection of cardiac risk without…
26 Sep 2023 Read summary →
NICE Respiratory / COPD / Asthma
Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment
Offer guided self-help digital CBT as a first-line intervention for children and young people presenting with mild to moderate anxiety or low mood symptoms,…
08 Feb 2023 Read summary →
NICE
Fetal monitoring in labour
Perform cardiotocography (CTG) on admission in labour for all women, then use intermittent auscultation with handheld Doppler at 15-minute intervals during active labour in…
14 Dec 2022 Read summary →
NICE Neurology
Multiple sclerosis in adults: management
Initiate disease-modifying therapy early: Start DMTs as soon as MS diagnosis is confirmed in relapsing-remitting MS, regardless of disability level, to reduce relapse rates…
22 Jun 2022 Read summary →
NICE Dermatology
Acne vulgaris: management
First-line treatment for mild-moderate acne: Prescribe topical retinoid (adapalene or tretinoin) as monotherapy, or combine with benzoyl peroxide or topical antibiotic to prevent bacterial…
25 Jun 2021 Read summary →
NICE Cardiology / Cardiovascular
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
Consider bempedoic acid with ezetimibe as a treatment option for patients with primary hypercholesterolaemia or mixed dyslipidaemia who are unable to tolerate statins or…
28 Apr 2021 Read summary →
NICE
Postnatal care
Conduct a comprehensive postnatal assessment within 24 hours of birth, including maternal physical examination, vital signs, and psychological wellbeing screening to identify complications early…
20 Apr 2021 Read summary →
NICE Infectious Disease
Neonatal infection: antibiotics for prevention and treatment
Intrapartum antibiotic prophylaxis is indicated for Group B Streptococcus (GBS)-positive mothers, those with unknown GBS status in preterm labour <37 weeks, or those with…
20 Apr 2021 Read summary →
NICE Women's Health
Ectopic pregnancy and miscarriage: diagnosis and initial management
Use quantitative hCG and transvaginal ultrasound together – diagnose ectopic pregnancy by combining serial hCG measurements (48-hour rise <53% is concerning) with transvaginal scan…
17 Apr 2019 Read summary →
NICE
Heavy menstrual bleeding: assessment and management
First-line pharmacological treatment: Offer levonorgestrel-releasing intrauterine system (LNG-IUS) as first-line, or tranexamic acid/NSAIDs if LNG-IUS unsuitable; combined oral contraceptives are second-line options for those…
14 Mar 2018 Read summary →
NICE Rheumatology
Osteoporosis
Assess fracture risk using FRAX or similar tool – Calculate 10-year probability of major osteoporotic fracture and hip fracture in all adults aged 50+…
28 Apr 2017 Read summary →
NICE
Low back pain and sciatica in over 16s: assessment and management
Avoid routine imaging for non-specific low back pain: Do not order X-rays, CT, or MRI for uncomplicated low back pain without red flags, as…
30 Nov 2016 Read summary →
NICE Diabetes / Metabolic
Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management
Assess all patients with MASLD using FIB-4 index or transient elastography to stratify fibrosis risk—those with advanced fibrosis require specialist hepatology referral and more…
06 Jul 2016 Read summary →
NICE Women's Health
Menopause: identification and management
Diagnose menopause clinically in women aged 45+ with vasomotor symptoms (hot flushes, night sweats) or mood changes without requiring FSH testing; use FSH only…
12 Nov 2015 Read summary →
NICE Oncology
Suspected cancer: recognition and referral
Use NICE 2-week wait referral criteria for suspected cancer – refer patients with relevant red flag symptoms (e.g., unexplained weight loss, persistent cough, dysphagia,…
23 Jun 2015 Read summary →
NICE
Fertility problems
Offer initial fertility assessment and advice to all couples who have not conceived after 12 months of regular unprotected intercourse (or 6 months if…
23 Oct 2014 Read summary →
NICE Women's Health
Ectopic pregnancy and miscarriage
Use serum beta-hCG measurement and transvaginal ultrasound as first-line investigations for suspected ectopic pregnancy or miscarriage; serial hCG levels help distinguish viable intrauterine pregnancy…
10 Sep 2014 Read summary →
NICE Mental Health / Psychiatry
Psychosis and schizophrenia in adults: prevention and management
Offer antipsychotic medication as first-line treatment for first-episode psychosis, combined with psychosocial interventions (CBT and family therapy), as monotherapy with either oral or long-acting…
12 Feb 2014 Read summary →
NICE Oncology
Ovarian cancer
Refer women with persistent pelvic pain, abdominal bloating, early satiety, or increased abdominal size to gynaecology using the urgent suspected cancer pathway—do not rely…
21 May 2012 Read summary →
NICE Oncology
Lung cancer in adults
Refer suspected lung cancer urgently – use the 2-week wait referral pathway for patients with symptoms suggestive of lung cancer (persistent cough, haemoptysis, chest…
26 Mar 2012 Read summary →
NICE Oncology
Breast cancer
Refer women with suspicious breast symptoms to breast specialist services urgently (within 2 weeks) if they meet NICE referral criteria, including persistent breast pain…
28 Sep 2011 Read summary →
NICE Oncology
Ovarian cancer: recognition and initial management
Recognise persistent symptoms requiring investigation: Report any persistent pelvic or abdominal pain, bloating, difficulty eating, or urinary/bowel changes lasting >2 weeks to your GP—these…
27 Apr 2011 Read summary →
NICE Oncology
Advanced breast cancer: diagnosis and treatment
Refer patients with suspected advanced breast cancer urgently to specialist breast units for staging imaging (CT chest/abdomen/pelvis, bone scan) and multidisciplinary team assessment before…
23 Feb 2009 Read summary →
You might also search for:
Oncology (826) Cardiology / Cardiovascular (374) Respiratory / COPD / Asthma (254) Infectious Disease (130) Gastroenterology (108) Diabetes / Metabolic (105) Neurology (101) Women's Health (89) Mental Health / Psychiatry (71) Dermatology (36) Rare Diseases (16)